ACR CONVERGENCE 2020—Tiphanie Phillips Vogel, MD, PhD, assistant professor of pediatrics and internal medicine at Baylor College of Medicine, Houston, moderated the session on COPA syndrome, which drew 324 attendees on a Sunday morning. This rare genetic cause of immune dysregulation can present like anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, lupus, lupus nephritis or rheumatoid…
In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.
Experts discuss how rheumatologists must consider the psychosocial aspect of care in the decision-making process for women when addressing their reproductive health needs, in addition to medication safety.
Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
During ACR Convergence 2020 in early November, the ACR and ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards and the ACR’s Distinguished Fellows. In addition, we bring you the first ever…
This ACR Convergence session discussed how recent advances in single-cell technologies are being used in rheumatic disease research.
ACR CONVERGENCE 2020—This has been a busy year for research publications covering a number of pediatric rheumatic diseases, including the emerging multi-system inflammatory syndrome (MIS-C) associated with SARS CoV-2. Despite the many challenges brought about by the COVID-19 pandemic, a healthy collection of publications covering a wide range of pediatric rheumatology research topics were published…
Roberto Caricchio, MD, discusses what trials of repurposed rheumatology drugs to treat COVID-19 cytokine storm have shown so far.
Uveitis is an umbrella term for intraocular inflammatory diseases that can lead to vision loss. It’s not just a concern for ophthalmologists. Uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients with reactive arthritis. The prevalence may be as high as 33% in…